Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2022-01-14 00:00:00 ET · period of report 2022-01-14 · accession 0000899243-22-002022 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-14 | 2022-01-14 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +10.0K | 482.2K | +2% | +$20.8K |
| D | 2022-01-14 | 2022-01-14 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $0.00 | -10.0K | 66.4K | -13% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-14 | M | A | 10,000 | $2.08 | 482,199 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-01-14 | M | D | 10,000 | $0.00 | 66,424 | D | $2.08 · — to 2029-05-22 | 10,000 Common Stock | (F1) The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. |